Gainers
- Forward Industries, Inc. FORD jumped 179 percent to $3.46 after the company reported the acquisition of Intelligent Product Solutions.
- NuCana PLC (ADR) NCNA shares gained 43.6 percent to $20.81 as the company announced plans to initiate a Phase 3 study of Acelarin in front-line advanced biliary tract cancer.
- Bioblast Pharma Ltd. ORPN shares surged 24.1 percent to $3.04.
- Sientra, Inc. SIEN shares rose 16 percent to $11.975. Stifel Nicolaus upgraded Sientra from Hold to Buy.
- Daxor Corporation DXR shares gained 13.3 percent to $4.8352.
- GWG Holdings Inc GWGH shares climbed 12.7 percent to $9.15 after the company disclosed a partner with the Beneficient Company Group in a transaction valued at up to $800 million including a $150 million cash investment.
- Ocular Therapeutix Inc OCUL gained 12.3 percent to $6.2214. BTIG Research upgraded Ocular Therapeutix from Neutral to Buy.
- Collegium Pharmaceutical, Inc. COLL shares rose 11.4 percent to $22.52.
- Iovance Biotherapeutics, Inc. IOVA shares gained 11.4 percent to $10.73.
- Acorda Therapeutics Inc ACOR climbed 10.2 percent to $27.55 amid M&A chatter. The biopharmaceutical company that focuses on improving the lives of people with neurological disorders is reportedly being targeted for an acquisition by Biogen Inc BIIB or Belgian-based UcB.
- Gridsum Holding Inc. GSUM shares rose 9.7 percent to $12.63.
- New Age Beverages Corporation NBEV shares climbed 9 percent to $3.486.
- PLx Pharma Inc PLXP gained 7.5 percent to $6.45. Janney Capital initiated coverage on PLx Pharma with a Buy rating and a $14.00 price target.
- Abercrombie & Fitch Co. ANF rose 4.4 percent to $19.78. Argus upgraded Abercrombie & Fitch from Hold to Buy.
Trending Investment Opportunities
Advertisement
Losers
- PAVmed Inc. PAVM shares tumbled 28 percent to $1.83 after the company reported public offering of common stock.
- Argos Therapeutics Inc ARGS shares dipped 23.2 percent to $2.00 after dropping 16.429 percent percent on Thursday.
- VivoPower International PLC VVPR shares dropped 16.1 percent to $2.24.
- MagneGas Corporation MNGA shares fell 13.3 percent to $3.58.
- Obalon Therapeutics, Inc. OBLN declined 13.2 percent to $5.33 after the company priced public offering of common stock.
- Netshoes (CAYMAN) Ltd NETS shares fell 10.9 percent to $8.00.
- GNC Holdings Inc GNC dropped 10.8 percent to $4.70 after climbing 51.59 percent on Thursday.
- Recon Technology, Ltd. RCON shares fell 9.1 percent to $2.63.
- Xplore Technologies Corp. XPLR shares declined 9 percent to $2.55. Xplore expects FY17 sales at the high end of its previously announced range of $75 million to $85 million. The company projects Q3 sales of $23.8 million.
- Dynatronics Corporation DYNT shares dipped 7.8 percent to $2.95.
- Inphi Corporation IPHI slipped 5.7 percent to $33.40. Morgan Stanley downgraded Inphi from Overweight to Equal-Weight, while Bank of America downgraded the stock from Buy to Neutral.
- International Business Machines Corp. IBM fell 4.2 percent to $162.17. IBM posted upbeat results for its fourth quarter, but issued FY18 EPS guidance below estimates.
- Mueller Water Products, Inc. MWA dropped 4.1 percent to $11.79. Cowen & Co. downgraded Mueller Water Products from Market Perform to Underperform.
- McCormick & Company, Incorporated MKC slipped 3.4 percent to $99.46. Deutsche Bank downgraded McCormick from Hold to Sell.
Loading...
Loading...
ANFAbercrombie & Fitch Co
$94.10-3.31%
Edge Rankings
Momentum
12.95
Growth
95.59
Quality
96.77
Value
80.46
Price Trend
Short
Medium
Long
BIIBBiogen Inc
$139.603.45%
COLLCollegium Pharmaceutical Inc
$37.741.56%
DXRDaxor Corp
$10.61-%
DYNTDynatronics Corp
Not Available-%
FORDForward Industries Inc
$13.79-5.93%
IBMInternational Business Machines Corp
$240.171.29%
IOVAIovance Biotherapeutics Inc
$2.585.31%
MKCMcCormick & Co Inc
$69.70-0.70%
MWAMueller Water Products Inc
$26.24-1.20%
NCNANuCana PLC
$3.85-7.23%
OCULOcular Therapeutix Inc
$12.62-0.24%
PAVMPAVmed Inc
$0.4409-3.35%
RCONRecon Technology Ltd
$2.67-0.77%
VVPRVivopower International PLC
$6.2910.2%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.